DK1983990T3 - Allosteriske A3-adenosin-receptormodulatorer - Google Patents

Allosteriske A3-adenosin-receptormodulatorer

Info

Publication number
DK1983990T3
DK1983990T3 DK07763034.1T DK07763034T DK1983990T3 DK 1983990 T3 DK1983990 T3 DK 1983990T3 DK 07763034 T DK07763034 T DK 07763034T DK 1983990 T3 DK1983990 T3 DK 1983990T3
Authority
DK
Denmark
Prior art keywords
adenosine receptor
a3rm
a3ar
allosteric
subject
Prior art date
Application number
DK07763034.1T
Other languages
Danish (da)
English (en)
Inventor
Johannes Brussee
Zhan-Guo Gao
Kenneth Jacobson
Aniko Goblyos
Adriaan P Ijzerman
Original Assignee
Us Gov Health & Human Serv
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Univ Leiden filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1983990T3 publication Critical patent/DK1983990T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DK07763034.1T 2006-01-26 2007-01-25 Allosteriske A3-adenosin-receptormodulatorer DK1983990T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76214106P 2006-01-26 2006-01-26
PCT/US2007/001930 WO2007089507A1 (en) 2006-01-26 2007-01-25 A3 adenosine receptor allosteric modulators

Publications (1)

Publication Number Publication Date
DK1983990T3 true DK1983990T3 (da) 2011-07-11

Family

ID=38116104

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07763034.1T DK1983990T3 (da) 2006-01-26 2007-01-25 Allosteriske A3-adenosin-receptormodulatorer

Country Status (10)

Country Link
US (2) US8420664B2 (https=)
EP (1) EP1983990B1 (https=)
JP (2) JP5414277B2 (https=)
KR (1) KR101383228B1 (https=)
CN (1) CN101410114B (https=)
AT (1) ATE502640T1 (https=)
DE (1) DE602007013359D1 (https=)
DK (1) DK1983990T3 (https=)
ES (1) ES2360632T3 (https=)
WO (1) WO2007089507A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
EP1983990B1 (en) 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US7906518B2 (en) * 2006-06-27 2011-03-15 Cbt Development Limited Therapeutic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CN101553459A (zh) * 2006-11-10 2009-10-07 诺瓦提斯公司 环戊烯二醇单乙酸酯衍生物
JP2012500255A (ja) * 2008-08-19 2012-01-05 ユニバーシテイト ライデン A3アデノシン受容体アロステリックモジュレーター
KR20120022919A (ko) * 2009-05-17 2012-03-12 캔-파이트 바이오파마 리미티드 안압의 감소를 위한 a3 아데노신 수용체 작동제
KR101971762B1 (ko) * 2012-08-09 2019-08-13 캔-파이트 바이오파마 리미티드 성기능장애의 치료에 사용하기 위한 a3 아데노신 수용체 리간드
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR20180134395A (ko) * 2016-04-19 2018-12-18 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
EP4499641A1 (en) * 2022-03-29 2025-02-05 The United States of America, as represented by the Secretary, Department of Health and Human Services A3 adenosine receptor positive allosteric modulators
WO2024014851A1 (ko) * 2022-07-12 2024-01-18 주식회사 넥스트젠바이오사이언스 Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물
IL300132A (en) * 2023-01-23 2024-08-01 Can Fite Biopharma Ltd Pancreatic cancer treatment
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007566A (ko) 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
EP1034207B1 (en) 1997-10-03 2005-03-02 Macromed Inc. BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES
KR20030076633A (ko) * 2001-02-05 2003-09-26 가부시키 가이샤 오오쯔카 세이야쿠 고우죠우 트리아조로퀴나졸린 및 피라졸로 트리아조로피리미딘유도체, 의약조성물,아데노신 에이3 수용체 친화제,안압저하제, 녹내장의 예방 및 치료를 위한 제제 및안압저하 방법
US20020179549A1 (en) 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2006503574A (ja) 2002-10-22 2006-02-02 カン−フィテ・バイオファーマ・リミテッド 疾患の状態に関するマーカーとしてのa3ar
JP2007517019A (ja) 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法
CA2585581A1 (en) 2004-11-22 2006-05-26 King Pharmaceuticals Research & Development Inc. Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
EP1983990B1 (en) 2006-01-26 2011-03-23 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services A3 adenosine receptor allosteric modulators

Also Published As

Publication number Publication date
US20090054476A1 (en) 2009-02-26
US8420664B2 (en) 2013-04-16
KR101383228B1 (ko) 2014-04-09
US20130197025A1 (en) 2013-08-01
WO2007089507A1 (en) 2007-08-09
CN101410114A (zh) 2009-04-15
EP1983990B1 (en) 2011-03-23
EP1983990A1 (en) 2008-10-29
DE602007013359D1 (de) 2011-05-05
KR20080099855A (ko) 2008-11-13
US9326978B2 (en) 2016-05-03
JP2009524668A (ja) 2009-07-02
ATE502640T1 (de) 2011-04-15
JP5414277B2 (ja) 2014-02-12
JP2013253108A (ja) 2013-12-19
CN101410114B (zh) 2012-07-04
ES2360632T3 (es) 2011-06-07

Similar Documents

Publication Publication Date Title
DK1983990T3 (da) Allosteriske A3-adenosin-receptormodulatorer
EP4506001A3 (en) SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS
UA94600C2 (en) Indole sulfonamide modulators of progesterone receptors
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
BRPI0517263A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
EA200870448A1 (ru) Тризамещенные 1,2,4-триазолы
ZA200801732B (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
BRPI0410418A (pt) fenil quinolinas e seu uso como moduladores do receptor de estrogênio
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
MX2007000273A (es) Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona.
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
GT200600254A (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
MX2007004765A (es) Compuestos y metodos que modulan la actividad de la trombopoyetina.
BRPI0510126A (pt) derivados de piperidina como moduladores do receptor de quimiocina ccr5
NO20073702L (no) Ikke-steroid glukocorticoid reseptor modulatorer
UY28974A1 (es) Derivados heterocíclicos de piperidina, composiciones que los contienen y procedimiento de preparación
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια